JAZZ Valuation
Jazz Pharmaceuticals PLC
$
117.120
- Overview
- Forecast
- Valuation
- Earnings
JAZZ Relative Valuation
JAZZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JAZZ is overvalued; if below, it's undervalued.
Historical Valuation
Jazz Pharmaceuticals PLC (JAZZ) is now in the Undervalued zone, suggesting that its current forward PE ratio of 5.33 is considered Undervalued compared with the five-year average of 8.24. The fair price of Jazz Pharmaceuticals PLC (JAZZ) is between 462.41 to 546.45 according to relative valuation methord. Compared to the current price of 117.12 USD , Jazz Pharmaceuticals PLC is Undervalued By 74.67%.
Relative Value
Fair Zone
462.41-546.45
Current Price：117.12
74.67%
Undervalued
5.33
PE
1Y
3Y
5Y
Trailing
Forward
7.40
EV/EBITDA
Jazz Pharmaceuticals PLC. (JAZZ) has a current EV/EBITDA of 7.40. The 5-year average EV/EBITDA is 7.54. The thresholds are as follows: Strongly Undervalued below 4.82, Undervalued between 4.82 and 6.18, Fairly Valued between 8.90 and 6.18, Overvalued between 8.90 and 10.26, and Strongly Overvalued above 10.26. The current Forward EV/EBITDA of 7.40 falls within the Historic Trend Line -Fairly Valued range.
5.94
EV/EBIT
Jazz Pharmaceuticals PLC. (JAZZ) has a current EV/EBIT of 5.94. The 5-year average EV/EBIT is 7.96. The thresholds are as follows: Strongly Undervalued below 4.82, Undervalued between 4.82 and 6.39, Fairly Valued between 9.53 and 6.39, Overvalued between 9.53 and 11.10, and Strongly Overvalued above 11.10. The current Forward EV/EBIT of 5.94 falls within the Undervalued range.
1.56
PS
Jazz Pharmaceuticals PLC. (JAZZ) has a current PS of 1.56. The 5-year average PS is 2.30. The thresholds are as follows: Strongly Undervalued below 1.23, Undervalued between 1.23 and 1.77, Fairly Valued between 2.83 and 1.77, Overvalued between 2.83 and 3.36, and Strongly Overvalued above 3.36. The current Forward PS of 1.56 falls within the Undervalued range.
7.80
P/OCF
Jazz Pharmaceuticals PLC. (JAZZ) has a current P/OCF of 7.80. The 5-year average P/OCF is 6.92. The thresholds are as follows: Strongly Undervalued below 3.26, Undervalued between 3.26 and 5.09, Fairly Valued between 8.75 and 5.09, Overvalued between 8.75 and 10.58, and Strongly Overvalued above 10.58. The current Forward P/OCF of 7.80 falls within the Historic Trend Line -Fairly Valued range.
4.82
P/FCF
Jazz Pharmaceuticals PLC. (JAZZ) has a current P/FCF of 4.82. The 5-year average P/FCF is 6.85. The thresholds are as follows: Strongly Undervalued below 3.70, Undervalued between 3.70 and 5.27, Fairly Valued between 8.42 and 5.27, Overvalued between 8.42 and 9.99, and Strongly Overvalued above 9.99. The current Forward P/FCF of 4.82 falls within the Undervalued range.
Jazz Pharmaceuticals PLC (JAZZ) has a current Price-to-Book (P/B) ratio of 1.85. Compared to its 3-year average P/B ratio of 2.25 , the current P/B ratio is approximately -17.74% higher. Relative to its 5-year average P/B ratio of 2.33, the current P/B ratio is about -20.27% higher. Jazz Pharmaceuticals PLC (JAZZ) has a Forward Free Cash Flow (FCF) yield of approximately 18.83%. Compared to its 3-year average FCF yield of 15.36%, the current FCF yield is approximately 22.63% lower. Relative to its 5-year average FCF yield of 12.78% , the current FCF yield is about 47.38% lower.
1.85
P/B
Median3y
2.25
Median5y
2.33
18.83
FCF Yield
Median3y
15.36
Median5y
12.78
Competitors Valuation Multiple
The average P/S ratio for JAZZ's competitors is 8.84, providing a benchmark for relative valuation. Jazz Pharmaceuticals PLC Corp (JAZZ) exhibits a P/S ratio of 1.56, which is -82.30% above the industry average. Given its robust revenue growth of 2.14%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of JAZZ increased by 0.98% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.77 to -17.08.
The secondary factor is the Revenue Growth, contributed 2.14%to the performance.
Overall, the performance of JAZZ in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
WFG
West Fraser Timber Co Ltd
76.050
USD
+5.22%
S
SentinelOne Inc
17.190
USD
+5.46%
BILI
Bilibili Inc
24.370
USD
+6.61%
ERJ
Embraer SA
58.710
USD
0.00%
ONB
Old National Bancorp
21.820
USD
+1.77%
CCCS
CCC Intelligent Solutions Holdings Inc
9.660
USD
+3.43%
BOKF
BOK Financial Corp
105.410
USD
+0.92%
CZR
Caesars Entertainment Inc
25.740
USD
+4.46%
WEX
WEX Inc
176.260
USD
+3.21%
RHI
Robert Half Inc
36.660
USD
+5.28%
FAQ
Is Jazz Pharmaceuticals PLC (JAZZ) currently overvalued or undervalued?
Jazz Pharmaceuticals PLC (JAZZ) is now in the Undervalued zone, suggesting that its current forward PE ratio of 5.33 is considered Undervalued compared with the five-year average of 8.24. The fair price of Jazz Pharmaceuticals PLC (JAZZ) is between 462.41 to 546.45 according to relative valuation methord. Compared to the current price of 117.12 USD , Jazz Pharmaceuticals PLC is Undervalued By 74.67% .
What is Jazz Pharmaceuticals PLC (JAZZ) fair value?
How does JAZZ's valuation metrics compare to the industry average?
What is the current P/B ratio for Jazz Pharmaceuticals PLC (JAZZ) as of Aug 14 2025?
What is the current FCF Yield for Jazz Pharmaceuticals PLC (JAZZ) as of Aug 14 2025?
What is the current Forward P/E ratio for Jazz Pharmaceuticals PLC (JAZZ) as of Aug 14 2025?